Pharmafile Logo

Patient Engagement for the Life Sciences

Patient Engagement for the Life Sciences, written by Guy Yeoman and Mitchell Silva with editorial and design support from Cuttsy+Cuttsy, explains the ‘why’ and the ‘how’ of patient engagement. It presents the compelling argument for why life science companies need to embrace and partner with patients and outlining an operating framework for doing it effectively.

Visit www.medipace.com/book to download your copy.

We’re really proud to have been working with Guy Yeoman and Mitch Silva on their new book, Patient Engagement for the Life Sciences. To celebrate the book launch, we’ve been talking to Guy about why patient engagement is so important to pharma. I’m a firm believer and I’m passionate about effective patient engagement. I think it delivers value for the industry, but also for patients and society at large. My background is in the pharmaceutical business. I’ve been working for the last two decades in the industry, and over the last three years I’ve built a patient-engaging capability for a large pharma organisation. So I come with that corporate, strategic background. The co-author of the book, Mitchell Silva, is a patient. He’s a patient expert himself, he’s a EUPATI scholar, and he’s built a virtual patient network for patients with cancer. So between us we bring both perspectives. We demonstrate clearly in the book why the industry needs to change, but also how it needs to change and what operating framework could be put in place that enables effective patient engagement, delivering value for both the industry as well as the patients and allied stakeholders.


This content was provided by Cuttsy + Cuttsy

Company Details

 Latest Content from  Cuttsy + Cuttsy 

Invited, but not equipped: patient involvement needs more than an open door

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

The outcomes are already chosen. So when can patients really shape them?

Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.

Long-term clinical trial engagement is a behavioural challenge – not just an informational one

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

Patients are telling the truth — just not to you

Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.

When what matters to patients is hard to measure

Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

A seat at the table: what the EU HTA reforms really ask of patient involvement

The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.

Why faster trials make participant understanding more important than ever

As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.

Older trial participants reject bad design, not technology

Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.

5 key takeaways from the Patient Centricity and Engagement Conference

Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.